Regression of early and intermediate stages of colon cancer by targeting multiple members of the EGFR family with EGFR-related protein

Cancer Research

Volumn 67, Issue 11, 2007, Pages 5389-5396

  Schmelz, Eva M ^a,b   Xu, Hu ^a   Sengupta, Radha ^a   Du, Jianhua ^a   Banerjee, Sanjeev ^a   Sarkar, Fazlul H ^a   Rishi, Arun K ^a   Majumdar, Adhip P N ^a,c  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADENOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ATTENUATION; CANCER INHIBITION; CANCER STAGING; CELL PROLIFERATION; CELL STIMULATION; COLON CANCER; CONTROLLED STUDY; DOWN REGULATION; FEMALE; INTESTINE INJURY; INTESTINE MUCOSA; INTESTINE TUMOR; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REMISSION; SMALL INTESTINE; STATISTICAL SIGNIFICANCE; THERAPY EFFECT; TUMOR VOLUME;

1,2-DIMETHYLHYDRAZINE; ADENOMA; ANIMALS; APOPTOSIS; CARCINOGENS; CELL GROWTH PROCESSES; COLONIC NEOPLASMS; DROSOPHILA PROTEINS; FEMALE; INTESTINAL MUCOSA; MALE; MICE; MICE, INBRED C57BL; NEOPLASM STAGING; NF-KAPPA B; PRECANCEROUS CONDITIONS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECOMBINANT FUSION PROTEINS; TRANSFORMING GROWTH FACTOR ALPHA;

EID: 34347249222     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-0536     Document Type: Article

References (48)

1. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366:2-16.
2. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
3. Allen LF, Lenehan PF, Eiseman IA, Elliot WL, Fry DW. Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 2002;29:11-21.
4. Takayama T, Katsuki S, Takahashi Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N Engl J Med 1998;339:1277-84.
5. Lee JC, Wang ST, Chow NH, Yang HB. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002;38:1065-71.
6. DiGiovanna MP, Stern DF, Edgerton SM, et al. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol 2005;23:1152-60.
7. Gullick WJ, Love SB, Wright C, et al. c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymphnodes. Br J Cancer 1991;63:434-8.
8. Ravdin PM, Chamness GC. The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers - areview. Gene 1995;159:19-27.
9. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001;7:1850-5.
10. Rubin Grandis J, Tweardy DT. Elevated levels of transforming growth factor a and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res 1993;53:3579-84.
11. Cunningh am MP, Essapen S, Thomas H, et al. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFRin colorectal cancer. Int J Oncol 2005;27:317-25.
12. Gibbs JB. Anticancer drug targets: growth factors and growth factor signaling. J Clin Invest 2000;105:9-13.
13. Ciardiello F. Epidermal growth factor receptor inhibitors in cancer treatment. Future Oncol 2005;1:221-34.
14. Yu Y, Rishi A, Turner J, et al. Cloning of a novel EGFR related peptide: a putative negative regulator of EGFR. Am J Physiol Cell Physiol 2001;280:C1083-9.
15. Xu H, Yu Y, Marciniak DJ, et al. Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther 2005;4:435-42.
16. Majumdar APN. Therapeutic potential of EGFR-related protein, a universal EGFR family antagonist. Future Oncol 2005;1:235-46.
17. Nautiyal J, Rishi AK, Majumdar APN. Emerging Therapies in Gastrointestinal Cancers. World J Gastroenterol 2006;12:7440-50.
18. Marciniak DJ, Moragoda L, Mohammad R, et al. Epidermal growth factor receptor related protein (ERRP): a potential therapeutic agent for colorectal cancer. Gastroenterology 2003;124:1337-47.
19. Levi E, Mohammad R, Kodali U, et al. EGF-Receptor Related Protein Causes Cell Cycle Arrest and Induces Apoptosis of Colon Cancer Cells in vitro and in vivo. Anticancer Res 2004;24:2885-92.
20. Moon WS, Tarnawski AS, Chai J, Yang JT, Majumdar APN. Reduced expression of epidermal growth factor receptor related protein in gastric mucosa. Gut 2005;54:201-6.
21. Marciniak DJ, Rishi AK, Sarkar FH, Majumdar APN. Epidermal growth factor receptor-related peptide inhibits growth of PC-3 prostate cancer cells. Mol Cancer Ther 2004;3:1615-21.
22. Zhang Y, Banerjee S, Wang Z, et al. Anti-cellular and anti-tumor activity of EGFR-Related Protein is mediated by inactivation of erbB receptors and NF-κB in pancreatic cancer. Cancer Res 2006;66:1025-32.
23. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987;37:147-51.
24. Roncucci L, Stamp D, Medline A, Cullen JB, Bruce WR. Identification and quantification of aberrant crypt foci and microadenomas in the human colon. Hum Pathol 1991;22:287-94.
25. Roncuci L, Medline A, Bruce WR. Classification of aberrant crypt foci and microadenomas in human colon. Cancer Epidemiol Biomarkers Prev 1991;1:57-60.
26. Cottrell S, Bicknell D, Kaklamanis L, Bodmer WF. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet 1992;340:626-30.
27. Sparks AB, Morin PJ, Kinzler KW. Mutational analysis of the APC/β-catenin/TCF pathway in colorectal cancer. Cancer Res 1998;58:1130-4.
28. Relan NK, Saeed A, Ponduri K, et al. Identification and evaluation of the role of endogenous tyrosine kinases in azoxymethane induction of proliferative processes in the colonic mucosa of rats. Biochim Biophys Acta 1995;1244:368-76.
29. Schmelz EM, Levi E, Du J, Xu H, Majumdar AP. Age-related loss of EGF-receptor related protein (ERRP) in the aging colon is a potential risk factor for colon cancer. Mech Ageing Dev 2004;125:917-22.
30. Normanno N, Bianco C, Strizzi L, et al. The ErbB receptors and their ligands in cancer: an overview. Curr Drug Targets 2005;6:243-57.
31. Cohen G, Mustafi R, Chumsangsri A, et al. Epidermal growth factor receptor signaling is up-regulated in human colonic aberrant crypt foci. Cancer Res 2006;66:5656-64.
32. Maurer CA, Friess H, Kretschmann B, et al. Increased expression of erbB3 in colorectal cancer is associated with concomitant increase in the level of erbB2. Hum Pathol 1998;29:771-7.
33. Moran AE, Hunt DH, Javid SH, et al. Apc deficiency is associated with increased EGFR activity in the intestinal enterocytes and adenomas of C57BL/6J-Min/+ mice. J Biol Chem 2004;279:43261-72.
34. Schmelz EM, Dillehay DL, Sullards MC, Merrill AH, Jr. Colonic cell proliferation and aberrant crypt formation are inhibited by dairy glycosphingolipids in 1,2-dimethylhydrazine-treated CF1 mice. J Nutr 2000;130:522-7.
35. Lemonnier LA, Dillehay DL, Vespremi MJ, et al. Sphingomyelin in the suppression of colon tumors: Prevention versus intervention. Arch Biochem Biophys 2003;419:129-38.
36. Shoemaker AR, Gould KA, Luongo C, Moser A, Dove WF. Studies of neoplasia in the Min mouse. Biochim Biophys Acta 1997;1332:F25-48.
37. Xiao ZQ, Moragoda L, Jaszewski R, et al. Aging is associated with increased proliferation and decreased apoptosis in the colonic mucosa. Mech Ageing Dev 2001; 122:1849-64.
38. Zhang Y, Banerjee S, Wang, ZW, et al. Epidermal growth factor receptor-related protein inhibits cell growth and induces apoptosis of BxPC3 pancreatic cancer cells. Cancer Res 2005;65:3877-82.
39. Preston-Martin S, Pike MC, Ross RK, Jones PA, Henderson BE. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415-21.
40. Majumdar APN, Du J, Hatfield JS, et al. Expression of EGF-Receptor Related Protein (ERRP) Decreases in the Gastric Mucosa During Aging and Carcinogenesis. Dig Dis Sci 2003;48:856-64.
41. Hu Y, Lee Leu RK, Young GP. Defective acute apoptotic response to genotoxic carcinogen in small intestine of APC(Min/+) mice is restored by sulindac. Cancer Lett 2006;248:234-44.
42. Wasan HS, Park HS, Liu KC, et al. APC in the regulation of intestinal crypt fission. J Pathol 1998;185: 246-55.
43. Eberhart CE, Coffey RJ, Radhika A, et al. Upregulation of cyclooxygenase2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183-8.
44. Otori K, Sugiyama K, Hasebe T, Fukushima S, Esumi H. Emergence of adenomatous aberrant crypt foci (ACF) from hyperplastic ACF with concomitant increase in cell proliferation. Cancer Res 1995;55:4743-6.
45. Baselga J, Mendelsohn J, Kim Y-M, Pandiella A. Autocrine regulation of membrane transforming growth factor α cleavage. J Biol Chem 1996;271:3279-84.
46. Xiao ZQ, Majumdar AP. Increased in vitro activation of EGFR by membrane-bound TGF-α from gastric and colonic mucosa of aged rats. Am J Physiol Gastrointest Liver Physiol 2001;281:G111-6.
47. Garrett TP, McKern NM, Lou M, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α. Cell 2002;110:763-73.
48. Moghal N, Sternberg PW. Multiple positive and negative regulators of signaling by the EGF-receptor. Curr Opin Cell Biol 1999;11:190-6.